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Summary
We use data from the New England and Wales Arrestee Drug Abuse Monitoring (NEW-
ADAM) programme to assess the validity of self-report measures of illicit drug use and to 
evaluate the use of alternative drug testing strategies within survey enquiries. Our analysis of 
the NEW-ADAM data reveals that bio-assay measurements of drug use tend not to be very 
sensitive to the cut-off levels selected for screening tests, a result that holds for cannabis, 
cocaine and opiates. We also show that a self-reported history of previous drug use can be 
used as a way of identifying individuals who are potential under-reporters of current drug use. 
This suggests a selective drug testing strategy which can reduce dramatically the cost of drug 
testing without comprising the accuracy of measurements of illicit drug use.
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01. Introduction
Illicit drug use and associated crime touch many people’s lives in modern society, with those 
affected ranging from the users and sellers of drugs, to parents, social groups and ultimately
government. Most research into the causes and consequences of illicit drug use makes use of 
self-reported consumption data, usually collected via social surveys (for example the British 
Crime Survey in the UK and the National Survey on Drug Abuse in the US). The difficulties
associated with self-reported data are widely recognised, particularly when the subject matter
is sensitive. Typically we expect some form of under-reporting from questions about drug 
use, and this is likely to vary between socio-economic groups. There is a growing literature 
that considers the validity of self-reported drug use by comparison with drugs tests on 
biological samples. Magura and Kang (1996) present a meta-analysis of 24 studies published 
since 1985. This review suggests that there tends to be only moderate agreement between 
self-reports and drug test results. For the original Drug Use Forecasting programme (the 
forerunner to the US Arrestee Drug Abuse Monitoring [US-ADAM] programme), Feucht et
al. (1994) report that juvenile male arrestees in Cleveland had very low self-report rates, with 
only 6% of those with cocaine-positive hair samples actually admitting cocaine use in the 
reference period.
More recent studies include that by Lu et al. (2001), who compared the self-report 
information of arrestees from the US-ADAM programme with the associated urinalysis data, 
focussing specifically on crack cocaine, but also cannabinoids, methamphetamines and 
opiates. The authors present a number of measures of concordance that reveal false-negative 
reporting to be the biggest problem, although the discrepancies are not as large as those 
reported by Feucht et al. (1994). The authors found that apart from cannabis, less than 50% of 
arrestees who tested positive for drugs actually admitted it. The rate for cannabis was 63.6%.
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Lu et al. also found that true-negative reporting rates were very high, with the majority of 
detainees who tested negative for drugs being accurate in their reporting of non-use. They 
also carried out a logit analysis of false reporting that revealed little difference between ethnic 
groups in reporting behaviour, except that Black arrestees were found to be less likely to 
under-report crack consumption than whites or Hispanics. A final point to note from this 
1 Although it is interesting to note that in a study into the drug use habits of a small sample of 182 HIV infected
or high-risk non-infected adolescents, Murphy et al. (2000) found that self-reported cannabis rates tended to be
slightly higher than urinalysis rates. 
1study is that other factors found to influence truthful reporting included past experience of 
drug treatment programmes and previous experience of arrest.
In another recent study, Mieczkowski et al. (1998) revisited the site originally studied 
by Feucht et al. (Cleveland), and a new site in Florida. Hair and urine samples were collected 
from 426 juvenile detainees in the 14-18 age range. They found that more drug use was 
revealed in samples than in self-reports, although this was less pronounced for cannabis. Like 
the Feucht et al. study, they also found that hair analysis revealed a greater rate of cocaine use 
than was revealed by urine testing. Substantial under-reporting of cocaine was also found by 
Appel et al. (2001), who compared the results of hair analysis to the self-reported drug use of 
a sample of 179 homeless/transient adults from New York, surveyed in 1994. The rate of self-
reported cocaine use was one third of that detected by hair analysis (64% of the sample had 
cocaine-positive hair samples whilst only 18% of the sample reported use in the past 30 days).
In this paper we investigate the validity of self-reported drug use in Britain, using 
drug-testing information collected through the New England and Wales Arrestee Drug Abuse 
Monitoring (NEW-ADAM) survey conducted in 1999-2001. We consider the sensitivity of 
false reporting rates to the calibration of assay-type drug screening tests. We then analyse the 
extent to which false reporting of illicit drug use can be predicted given information about the 
individual’s personal characteristics and history of drug use. We go beyond the existing 
literature by considering the implication of this for survey design, by developing two 
alternative selective drug-testing strategies, which can reduce survey costs by implementing
tests only in cases where there is predicted to be a significant danger of under-reporting.
In the next section the practicalities of drugs testing are discussed, including the types 
of tests that can be done, the biological samples that can be used, the differences between 
screening and confirmatory testing, and the calibration of drugs tests. We then analyse the 
validity of self-reported drug use using data from the NEW-ADAM programme. Section 4 
proposes some selective drug testing strategies and assesses their accuracy, Section 5 
concludes.
2. Bio-assay as a measurement device
2.1. Screening and Confirmatory Testing 
The presence of drugs in a biological sample is typically detected via immunoassay or 
chromatography, which are used to detect the metabolites of the drugs produced by the body 
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presence of metabolised drugs in a sample of blood, urine, saliva, hair or sweat. A biological 
sample is taken and subjected to the screening test. The test is calibrated against pre-
determined cut-offs that indicate the presence of drugs in the biological sample (see below for 
more details of the cut-offs). Whereas other ADAM programmes such as those in the U.S. 
(US-ADAM) and Australia (DUMA) use the Enzymes Multiplied Immune Testing (EMIT) 
screening test (Makkai, 2000), NEW-ADAM used the ‘On-Line’ Kinetic Interaction of 
Micro-Particles (KIMS) test. The choice of the KIMS test for NEW-ADAM was based on ‘a 
balance of its cheapness and acceptable levels of accuracy’ (Bennett, 1998, p.13).
Screening tests usually involve the use of a competitive binding immunoassay to 
detect the presence of drugs in a biological matrix. The choice of biological sample and the 
particular testing kit used will determine what drugs of abuse can be tested for. The urine 
samples in NEW-ADAM were tested by the Forensic Science Service (FSS), for seven drug 
types including opiates, cocaine, canabinoids and amphetamines. Although screening tests are 
relatively inexpensive (currently around £10-£15 per test for saliva and urine samples), they 
are subject to two limitations: specificity and cross-reactivity (Makkai, 2000; Bennett, 1998). 
Typically, screening tests do not identify specific chemical compounds present in biological 
samples, and hence it is not possible to separately identify cocaine from crack, and 
amphetamine from ecstasy. This problem of specificity is not unique to KIMS (see discussion 
below), although it is suggested that the EMIT test ‘is considered to have high sensitivity and 
moderate specificity’ (Makkai, 2000, p. 13). Cross-reactivity is perhaps a bigger concern 
when using screening tests in the context of the Criminal Justice System. This problem relates 
to false-positive results, whereby consumption of legal substances (e.g. codeine-based pain 
killers or poppy seeds) can give rise to detectable traces of morphine or codeine in urine and 
hence a positive screening test (this is discussed in more detail below).
The typical approach to overcoming the uncertainties of screening tests is to subject 
samples that test positive to a confirmatory test (the alternative is to conduct a confirmatory
test on randomly selected samples). Confirmatory tests are far more accurate than screening 
tests, but considerably more expensive. They were not used in NEW-ADAM (Bennett, 1998, 
p.91), but have been used in the Australian DUMA for opiates, amphetamines and 
benzodiazepines. The typical confirmatory test is undertaken by use of Gas Chromatography-
Mass Spectrometry (GCMS), although there are recent developments such as capillary 
electrophoresis-mass spectrometry that offer an acceptable alternative (Ramseier et al., 2000). 
3In this section we give a brief description of the metabolites from the common drugs of abuse 
that are detected by the standard GC-MS confirmatory tests, concentrating on cannabinoids, 
cocaine and the opiates (see Goldberger and Cone, 1994 for further detail). 
2.1.1. Cannabinoids 
The most prevalent metabolite of tetrahydrocannabonal (THC) present in cannabis and the 
cannabinoids is 11-nor-'
9-tetrahydrocannabinol-9-carboxylic acid (THC-COOH). This will 
be detected in most biological samples regardless of the method of ingestion. It is unlikely 
that THC-COOH will be detected in biological samples taken from individuals who have 
passively consumed cannabis smoke, unless this has happened for a long duration in a totally 
unventilated room.
2.1.2. Cocaine 
The main metabolite of cocaine is benzoylecgonine and the body rapidly creates this through 
hydrolisation following ingestion. The extraction of benzoylecgonine from biological samples
is very straightforward and it can be present in some samples for several days after ingestion. 
It is possible that benzoylecgonine will be detected in biological samples following 
consumption of certain ‘health teas’ that are prepared with coca leaf, although these are quite 
rare. There is a possibility that benzoylecgonine can also be detected in the urine of 
individuals who have been passively exposed to the vapours of cocaine base (crack) as it is 
smoked. Generally it is difficult to determine whether cocaine metabolites found in specimens
are from the powder form that has been insufflated (‘snorted’) or injected from the freebase 
form (crack). Lu et al. (2001) suggest that testing for anhydroecgonine methyl ester can give 
direct evidence of smoking crack as this is produced as crack cocaine is heated and is rarely 
present when the powder form is consumed.
2.1.3. Opiates 
Following consumption, heroin (diacetylemorphine) is metabolised first into 6-
monoacetylmorphine (MAM) and then into morphine. Morphine is further metabolised into 
morphine-glucuronide and normorphine. The primary metabolites found in biological samples
are morphine and morphine-glucuronide, although MAM may also be present (a definite 
4indication of heroin consumption). Codeine is often found as it is frequently present in heroin 
street samples. When consumed, codeine is metabolised to codeine-glucuronide, morphine
and norcodeine, although codeine and morphine are the primary metabolites found in 
biological samples. The main problem with opiates is that although the GC-MS analysis will 
separately identify, say, codeine and morphine, it usually fails to differentiate between 
morphine and codeine deriving from the ingestion of some over-the-counter medicines and 
even poppy seeds, which are widely used in baking. Alternative indicators of heroin such as 
acetylcodeine, which is an impurity of heroin synthesis, have been considered in the literature 
(see for example Staub et al., 2001), but these tend to be more useful in detecting illicit use of 
street heroin in individuals engaged in treatment programmes.
2.2. Biological samples 
There are five alternative samples that can be taken for drug testing: blood, urine, saliva, 
sweat, and hair. Each of these has its relative merits in terms of cost, ease of collection, 
openness to adulteration, and the window of exposure. There is an extensive literature on the 
use of different biological samples for drugs testing (e.g. Baer and Booher, 1994; Kerrigan 
and Phillips, 2001; Kidwell et al., 1998; Kintz, 1996; Makkai, 2000; Navarro et al., 2001; 
Osselton et al., 2000; Pichini et al., 2002; Sachs and Kintz, 1998; Skopp and Potsch, 1999), a 
synthesis of which is presented below.
2.2.1. Blood 
Most drug types and their metabolites are passed into the blood system, although their 
concentration can be quite low and give rise to a window of detection of only 24-36 hours. 
The biggest drawback with blood is that screening can only be done in the laboratory and 
given its invasive nature can only be taken as a sample by medically trained staff. In the 
context of drugs testing of arrestees, blood sampling is probably not feasible given its cost, 
the potential for infection, and the environment in which it would have to be taken. 
2.2.2. Urine 
Urine is the most widely used biological sample for drugs testing in the Criminal Justice 
System and in the workplace. Drugs tend to be relatively more concentrated in urine (e.g. 10-
5100 times more concentrated than in blood) due to the way in which the kidney filtrates the 
blood and concentrates the by-products. Urine testing has a cost advantage as much of the 
preparation of samples can be automated. One drawback is that sample collection and 
handling is relatively intrusive and unsavoury, which can be problematic for survey 
interviewers. A further problem with urine is that it is relatively easy to adulterate the sample
(for example, excessive dilution through water consumption or through the use of commercial
test evasion products). These are not usually serious concerns in the survey context.
2.2.3. Saliva 
Saliva can be used to screen for the presence of heroin, dihydrocodeine, codeine, morphine,
cocaine (and its principle breakdown product), and benzoylecgonine. Is not as useful for 
detecting cannabis, as the molecules tend to be too big to pass into the saliva. The window of 
detection for most drugs in saliva is similar to that for blood as oral fluid is formed from the 
circulating blood (drug metabolites pass into saliva through tissue membranes from the blood 
plasma). The amount of drug metabolite present in saliva will depend on the method of 
consumption, the acidity of the oral fluid, and the elapsed time since the dose was taken.  It is 
difficult to adulterate saliva as it is continuously produced in the mouth then swallowed and 
collection can be easily observed without invading privacy. The main difficulty is with ‘dry-
mouth’, which can be caused by cannabis, amphetamine and opiate use. Consuming some
over-the-counter travel sickness preparations can also produce a dry mouth. The implication
of ‘dry mouth’ is that it takes longer to achieve an appropriate volume of sample and may
therefore threaten the response rate in voluntary surveys.
2.2.4. Sweat
Most drugs of abuse are excreted by the body in sweat, and in some case heroin molecules, in 
addition to the metabolites, have been detected in this matrix. The window of detection is not 
as long as urine, but certainly better than blood. The biggest problem with sweat is its 
collection, since one cannot expect an arrestee to secrete a sufficient sample of sweat within 
the usual time frame of an interview. One practical method that has been developed is the 
‘sweat patch’, which acts as a container for the non-volatile components of sweat. Presuming
that the patch cannot be tampered with, it is fairly secure against adulteration as the material
used does not allow non-volatile substances from the environment to penetrate it. 
6Unfortunately the sweat patch is not practical in the context of the Criminal Justice System, as 
it has to be worn for several days before a sufficient volume of sweat is collected for analysis. 
2.2.5. Hair 
Hair can be used to detect most of the main drugs of concern including the main cocaine and 
heroin metabolites, and has the benefit of detecting THC-COOH rather than just THC, which 
can come from environmental exposure. One advantage of hair is that is can give a fairly 
accurate picture of the individual’s recent drug history, plus it can give a more accurate 
measure of concentration than, say, urine. It would also appear that hair samples give a much
more accurate indicator of cocaine, and that individuals who use cocaine infrequently or at 
low dosage levels are less likely to be screened positive with urine samples (Mieczkowski et
al., 1998). A further benefit of using hair is that it is fairly difficult to adulterate the sample
(although some intensive hair preparations can affect the analysis). Against this, hair testing is 
expensive relative to urine and cannot be tested on-site. There are also obvious problems if 
the detainee does not have any visible hair. The biggest advantage in using hair is the wide 
window of detection (a two-inch strand can capture approximately four months’ worth of 
drug exposure), although it should be noted that there is a latency period of between three to 
seven days before drugs are deposited in the hair (Appel et al., 2000).
2.3. Choosing the cut-off 
Screening tests usually require the analyst to visually detect the presence or absence of a 
coloured band or line on a chemically impregnated membrane following exposure to the 
sample. This is then calibrated against a pre-determined scale according to the colour of the 
band that gives an indication of the concentration of the drug in the sample. A positive or 
negative result is given by reference to cut-off levels of concentration (this may be achieved 
automatically with an electronic test reader). The cut-off levels used in the NEW-ADAM and 
DUMA studies are given in Table 1 (also shown are the cut-offs used in Leino et al.’s (2001) 
comparison of eight on-site screening devices). The NEW-ADAM cut-offs were agreed in 
consultation with the FSS, whilst the DUMA cut-offs were set by the official body Standards 
Australia. There is some variation in these cut-off levels across the three studies, particularly 
for amphetamines, but also for cocaine where the NEW-ADAM cut-off is half the level used 
in DUMA and by Leino et al. Bennett (1998, 2000) does not define the criteria used to 
7determine these cut-offs, although it appears to follow common practice of setting cut-offs 
quite high to minimise false-positive results. Although this is appropriate in legal contexts, it 
is a potential source of bias for a prevalence survey, where one would like the cut-off to give 
a reasonable balance between false negatives and false positives.
Table 1. Cut-offs used in NEW-ADAM and DUMA*
Drug Type  NEW-ADAM DUMA Leino et al.
Amphetamines 500 300 1000
Benzodiazepines 100 100 -
Cannabis 50 50 50
Cocaine 150 300 300
Methadone 300 - -
Opiates 300 300 300
* Source: Bennett (2000) and Makkai (2000). 
In the following section we use data from the NEW-ADAM study to consider further the 
sensitivity of test results and their concordance with self-reporting to the specified cut-off
levels for cannabis, cocaine and opiates. 
3.  An analysis of NEW-ADAM data 
3.1. The NEW-ADAM data
The NEW-ADAM survey was conducted annually (from 1999 to 2001) over a thirty-day period, 
and yields information on approximately 1500 arrestees collected at eight police custody suites, 
rotated on a two-year cycle. Interviewing of arrestees was by consent, and a typical interview 
lasted for twenty minutes after which a urine sample was collected from the individual (again, by 
consent, given at the start of the interview process). The interview covered areas such as self-
reported drug and alcohol use, criminality and contact with drug treatment services. For more
details of the NEW-ADAM methodology see Holloway and Bennett (2003).
With respect to the sampling process, all arrestees entering the participating custody 
suites were assessed by the interviewers for eligibility to be interviewed, although in some cases 
the custody officer will have made this assessment on the basis of interviewer safety. Typical 
8reasons for non-eligibility were that the arrestee was not fit due to alcohol or that there is 
insufficient time in the custody process for an interview to take place. In addition, juveniles, 
prison transfers and those held only for breath tests were ineligible, as were arrestees with mental
health problems or insufficient English language skills. The result of this selection process is that 
the pool of eligible arrestees was typically less than 50% of the throughput of the participating 
custody suites. Moreover, on average only 50% of eligible arrestees were interviewed for NEW-
ADAM, although this varied considerably across participating sites. In addition to response rate 
problems, NEW-ADAM is also considered to be unrepresentative of arrestees. This is mostly
because NEW-ADAM only involved a small number of not necessarily representative custody 
suites, which tended to be relatively large ones situated in areas with relatively high levels of
social deprivation and drug abuse. The full extent of the limitations of the NEW-ADAM data are 
discussed in Pudney et al. (2003), whilst a detailed feasibility study to improve the design of the 
survey is reported in Boreham et al. (2003). Some of the problems arising from the NEW-ADAM
design are also discussed in Bird et al. (2002).
3.2. Robustness of test results and conflict with self-reported drug use 
Given the nature of the NEW-ADAM process, it is possible that our results will be affected by 
the arrestees’ prior knowledge that a drugs test will be done at the end of the interview (on 
average, 95% of arrestees consenting to be interviewed also gave consent for a urine sample to be 
taken). Conceivably, if an arrestee knew that he or she would be tested for drugs after answering 
questions about drug use, then that individual has a greater incentive not to false report. However, 
as we shall see later, despite this, there is still a large amount of apparent misreporting of drug use 
in the NEW-ADAM sample. Before we compare the drug test results with self-reported drug use, 
we begin by considering the dispersion of screening test results in the NEW-ADAM sample. The 
distributions of NEW-ADAM tests scores (calibrated in Ng/ml) for cannabis, cocaine, and 
opiates are shown in Figures 1-3 respectively.
2 What these show is that the distribution of test 
results tends to be bimodal, with a large number of arrestees providing samples with a reading 
around zero and another group providing samples at a much higher positive value at or beyond 
the NEW-ADAM cut-off level. This is particularly pronounced for cannabis, although still 
apparent for cocaine and opiates.
2 Note that the test scores are calibrated in such a way that negative values are possible. Figures 1-3 show non-
parametric kernel density estimates.
9Figure 1. The distribution of test scores for cannabis (cut-off 50 Ng/ml)
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10Figure 2. The distribution of test scores for cocaine (cut-off 150 Ng/ml)
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Figure 3. The distribution of test scores for opiates (cut-off 300 Ng/ml)
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11Our next concern is the concordance between the self-reported drug use of NEW-ADAM
interviewees
3 and the drugs test results. Given the distribution of test scores revealed in Figures 
1-3, we are also interested in how sensitive concordance is to the cut-off levels used to determine
a positive screening test. Table 2 shows the relationship between reporting rates and test results 
for cannabis, cocaine and opiates, covering a number of recall periods. It should be noted, 
however, that concordance is most relevant when screening test results are compared to the past 
three days recall period, rather than longer periods such as the past 12 months, although this 
longer recall period is of relevance in determining an optimal testing strategy (see below). The 
results in Table 2 are given for five different cut-off levels centred on the NEW-ADAM level. In 
general we find that as the cut-off level is increased the percentage of samples testing positive for
any of the drugs falls, although there is not a great deal of variation in the rates for opiates and 
cocaine. However, there is more noticeable variation for cannabis. False-negative reporting is 
particularly high for cocaine at all the cut-offs used, with a 35% average rate of positive tests for
individuals reporting no use in the past three days. This may reflect the window of detection for 
cocaine, but it should be noticed that there is still a 20% rate of false-negative reporting for 
individuals who report no use of the drug in the past month, and a 9% rate for those who claim no 
use ever. This pattern is also seen for opiate use, although it is slightly less pronounced. Cannabis 
users appear to be the most truthful (as reported earlier) with only 2-3% of those claiming no use 
providing a positive test result, although the false-negative reporting is quite high (around 20%) 
for individuals who claim no use in the past three days. This could be partly a window of 
detection problem, but it should be noted that false-positive reporting is most pronounced for 
cannabis, with around 16% of those claiming some use in the past three days testing negative (a 
range of 13.3% to 20% depending on the cut-off level used). Overall these results do not compare
well with the reported concordance rates for the Scottish pilot of ADAM (McKeganey et al.,
2000). Although the Scottish ADAM involved a much lower number of participants (there were 
427 interviews yielding 280 useable urine samples), comparison of self-reported drug use and 
urinalysis results show very high rates of concordance for heroin, cocaine and heroin in the range 
of 86% to 97%.
3 The NEW-ADAM survey used traditional paper-based interviewing. For a discussion of the relative merits of 
computer-aided or paper-based interviewing see Flood-Page et al. (2000).
12Table 2. Sensitivity of test results to cut-off levels 
Cut-off
%
testing
positive
% of those 
testing positive 
claiming no use 
in last 3 days 
% of those testing
negative claiming
some use in last 3
days
% of those 
testing positive 
claiming no use 
in last month
% of those 
testing positive 
claiming no use 
ever
Cannabis
30 53.7 24.3 13.3 10.4 3.2
40 50.6 22.2 15.2 9.5 2.8
50 47.9 20.4 16.7 8.5 2.5
60 45.9 19.9 18.7 8.2 2.6
70 44.0 18.9 20.0 7.7 2.2
Cocaine & Crack*
100 23.3 37.2 2.5 21.3 10.2
125 22.6 35.8 2.7 20.6 9.9
150 21.9 35.2 3.0 20.4 9.4
175 21.6 34.8 3.2 20.2 9.5
200 21.4 34.6 3.3 20.1 9.5
Opiates
200 31.7 23.2 1.0 18.3 10.6
250 31.5 22.6 1.0 17.8 10.0
300 30.9 21.4 1.1 16.6 8.9
350 30.8 21.2 1.2 16.5 8.8
400 30.5 20.8 1.3 16.4 8.7
* These include individuals who report recent use of prescription medicines; exclusion of these cases makes little 
difference to the sample proportions.
To explore the relationship between false reporting and the screening test cut-off levels 
further, we now examine the proportions of test results that are either very close to or very far 
from the cut-off levels. Table 3 relates to the results for those individuals who claim no drug use 
in the past three days but who test positive for drugs, whilst Table 4 covers those who test 
negative but report drug use in the past three days. What these figures reveal is that most
apparently false reporting is not in cases where test results are very close to the cut-off level. In 
table 4 only a tiny proportion of positive tests are within 10% of the cut-off levels, whilst most
are at least 150% above the cut-off. Similarly, for negative test results for those claiming drug use 
in the past three days, only a small proportion of the tests are within 10% of the cut-off level, 
whilst the majority, particularly for cocaine and opiates, are below 50% of the cut-off level for all 
the ranges of cut-offs we have used. This is strong evidence that apparent misreporting is indeed 
that - a definite attempt to conceal or exaggerate recent drug use, rather than an artefact of the 
testing process. 
13Table 3. Test scores of individuals who test positive but claim no drug use within last 3 days 
Cut-off
Number of 
cases
Mean test 
score
% within 10% 
of cut-off 
% above 150% 
of cut-off 
Cannabis
30 373 83 4 81
40 321 91 3 81
50 280 97 3 84
60 261 101 4 75
70 238 104 2 42
Cocaine & Crack 
100 248 562 2 89
125 231 595 2 92
150 221 616 2 94
175 215 628 1 91
200 212 635 2 87
Opiates
200 210 587 1 90
250 203 599 3 89
300 189 623 1 95
350 186 628 3 95
400 181 635 0 95
Table 4. Test scores of individuals who test negative but claim drug use within last 3 days 
Cut-off
Number of 
cases
Mean test 
score
% within 10% 
of cut-off 
% below 50% 
of cut-off 
Cannabis
30 176 14 8 54
40 214 18 7 59
50 249 22 7 59
60 289 26 9 58
70 320 30 7 60
Cocaine & Crack 
100 55 7 2 95
125 59 15 3 88
150 68 31 7 78
175 71 37 4 76
200 73 41 3 75
Opiates
200 19 30 0 95
250 20 41 5 90
300 22 64 9 82
350 23 75 4 78
400 25 98 8 76
143.2. Who are the under- and over-reporters? 
One issue that can be explored with the NEW-ADAM data is whether or not individual false 
reporting can be predicted. To do this we estimate two logit models of false reporting. In the first 
we consider the probability of generating a positive test result given no reported drug use in the 
past three days, whilst in the second we consider the occurrence of a negative test result for those 
who claim to have used drugs in the past three days. Note that we are modelling the probability of
misreporting conditional on self-reported drug use, not conditional on the test result. The reason 
for this is that we want to explore the use of the model in survey design, as the basis for a 
selective testing strategy. During the interview, self-reported drug use information is immediately
available and can be used automatically to determine whether or not a subsequent drug test 
should be administered.
The dependent variable is a binary indicator of a having positive/negative test result and 
we include explanatory variables to control for self-reported drug use, offending behaviour and 
the demographic characteristics of the respondent. This specification is similar to Lu et al. (2001), 
although other covariates that were not statistically significant in any of the models have been 
dropped (e.g. gender and offence class for the first model and some of the self-reported drug use 
in the second model). These were also found to be insignificant in the Lu et al. study. The model
was estimated for cannabis, cocaine, opiates and a composite category of ‘any hard drug’. The 
results for the false-negatives model are reported in Table 5 and those for false-positives in Table 
6.
15Table 5. Logit coefficients for the occurrence of a positive drug test among those who report no 
drug use within last three days 
Covariate Cannabis Cocaine & 
Crack Opiates Any hard drug 
Intercept   -25.130 
***  -42.422 
*** -16.367
* -28.308
***
Self-report use in last 30 days    0.117 
*** 1.203
*** 0.056
** 0.804
***
Self-report use in last year    0.910 
*** 0.153 1.552
*** 0.657
***
Self-report use ever  0.209 0.589
** 0.985
*** 0.469
**
Suspected of drug offence  -0.025       0.487 
** -0.133 0.214
ln(age)    14.486 
***    23.886 
*** 7.457 15.178
***
ln(age)
2  -2.287 
***     -3.594 
*** -1.023 -2.209
***
N 1519 2384 2142 1983
Goodness of fit F
2(8) 13.4 8.5 9.0 3.7
Mean predicted probability 0.184 0.093 0.088 0.133
Range of predicted probabilities  0.006 – 0.920 0.002 – 0.426  0.027 – 0.800  0.020 – 0.476 
Note: *** = pd0.01; ** = pd0.05; * = p 0.10 d
Table 6. Logit coefficients for the occurrence of a negative drug test among those who 
report drug use within last three days 
Covariate Cannabis Cocaine & 
Crack Opiates Any hard 
drug
Intercept -1.160   3.860
** 0.913 4.231
At least 24 offences in last year 0.611
*** -0.183 0.519 -0.394
Self-report use in last 30 days -0.051
*** - -0.098
*** -
ln(age) 0.125 -1.653
***   -0.777 -2.175
***
Female 0.168 -1.249
*** 0.097 -0.862
N 1339 473 716 874
Goodness of fit F
2(8) 11.7 4.2 3.7 10.3
Mean predicted probability 0.186 0.144 0.031 0.043
Range of predicted probabilities  0.088 – 0.511 0.020 – 0.305  0.006 – 0.278  0.005 – 0.127 
Considering first the results in Table 5, it is clear that self-reported past drug use does 
provide useful predictors of a positive drug test for those claiming no drug use in the past 
three days. In all cases the estimated effects of declared drug use in the last month, year or 
ever are positive and mostly statistically significant. In other words, if an arrestee claims not 
to have used a drug in the past three days, but reports some past drug use, then that individual 
has a much higher probability of generating a false negative observation. Age has a 
significant nonlinear impact, with the probability of a false negative rising up to a critical age 
and then falling thereafter. The peak age is at 24 years for cannabis but 31 years for the 
combined hard drug category (cocaine plus opiates). 
16For individuals testing negative but claiming the use of the drug in the past three days, the 
results reported in Table 6 do not suggest a clear pattern across drug types. For example, whereas 
an individual who has carried out at least 24 offences in the past year is more likely to falsely
report cannabis in the past three days, this is not the case for cocaine and opiates. For cocaine, 
females are less likely than males to falsely report use in the past three days, whereas individuals 
who report drug use in the past 30 days are less likely to falsely report opiate use in the past three 
days, a result that also holds for cannabis. There is some evidence of a declining probability of a 
false positive with age and also a smaller probability for women. Although this corresponds with 
the common perception of young males as the group most prone to bragging about their illicit 
exploits, the evidence is far from consistent. 
Using the estimated coefficients from the model, we can calculate the predicted 
probability of misreporting for each individual, conditional on the explanatory covariates. Tables 
5 and 6 report the range of these predicted probabilities for all the individuals in the data. 
Looking first at the probability of a false negative (a positive test result with no self-reported drug 
use in the past three days), we see from Table 5 that the range of predicted probabilities is wide, 
particularly for cannabis, where the probability of conflict between test and self-report varies 
from 0.006 to near-certainty (0.920), depending on the individual’s characteristics. The range is 
narrower for cocaine, but still substantial. The spread of predicted probabilities is generally less in 
Table 6 for false positives. Again cannabis shows the widest range. These large variations in 
individual probabilities of misreporting suggest that there is considerable scope for using 
selective drug-testing in surveys like NEW-ADAM, where the cost of drug testing is a major
constraint on survey design. 
4. Drug testing strategies
In this section we consider ways in which selective drug testing can be implemented to give 
acceptably accurate measurement of drug use by arrestees at lower cost than a universal testing 
policy. The question here is whether it is possible to devise a ‘smart’ version of Computer
Assisted Personal Interviewing, in which the programme determines whether or not a sample
should be taken for drug testing based on the arrestee’s previous responses to questions on drug 
use history and other relevant characteristics. 
174.1. Full and partial testing strategies
We now consider the accuracy, relative to the NEW-ADAM urine test results, that would 
have been yielded by alternative partial testing strategies. In doing this, we concentrate on the 
problem of false negative responses, since false positives are relatively infrequent and less clearly 
related to observable attributes of the individual. 
A partial testing strategy results in the following composite indicator of recent drug use: 
°
¯
°
®
­
 
otherwise 0
positive is result  test   the and  test  drug for elected if 1
days 3 last  within  use drug reported - self but  test, drug for selected not if 1
s Di (1)
A major focus of surveys like NEW-ADAM is the measurement of the volume of crime
committed by problem drug users. To examine this, we consider the measurement of the 
prevalence amongst arrestees of drug-using repeat offenders, identified by the following 
qualitative variable: 
°
°
¯
°
°
®
­
 
otherwise 0
year previous in the
offences 24 least at committed have  to claims respondent  the if i
i
D
R (2)
The prevalence of drug use and drug-related crime is then measured by the sample means of the 
binary variables Di and Ri.
We evaluate five different strategies based on the following alternative criteria for
selection for drug testing: 
No testing 
Selected for test if claims no drug use in last 3 days 
Selected for test if claims no drug use in last 3 days but some in the last month
Selected for test if claims no drug use in last 3 days but some in the last year 
Selected for test if claims no drug use in last 3 days but some use ever. 
The analysis is done for a single “hard” drug category consisting of cocaine (including 
crack) and opiates combined and the results are summarised in Table 7. This shows clearly the 
18trade-off between the number of cases that need to be tested and the number of false negatives 
generated by the process. If all arrestees who report no drug use in the last three days are tested 
then this has the biggest impact on the number that need to be tested (69% of the sample), but 
reduces the number of false-negatives in the composite process to zero. As we tighten the 
selection criterion for testing by including only a subset of those reporting no hard drug use in the 
last three days, the number of required tests increases slowly, from 8% of the sample for the ‘last 
month’ criterion to 27% for the ‘ever’ criterion. At the same time, the total number of false 
negatives is reduced by more than half (from 178 to 88).
The discrepancy in measured prevalence (relative to universal testing) is also shown in 
Table 7. If no-one is tested then we underestimate prevalence by 20.5% due to false negative 
self-reporting of drug use in the last three days. This discrepancy is almost halved by testing 
the 8% of the sample who report no hard drug use in the last three days but some use in the 
last month. By testing all those who admit to some past hard drug use, the discrepancy can be 
reduced to only 4.7%. For the corresponding measure of drug-related crime (the mean of Ri)
the under-estimation is reduced from the low figure of 4.4% without drug testing to zero by 
testing all self-declared ‘last month’ users. More extensive testing results in apparent over-
adjustment since false positives are not corrected by this strategy. Note that, unlike drug use, 
there is no external check available for self-reported offending rates, so the apparently 
accurate estimate of the prevalence of drug-related crime may still be heavily contaminated
by reporting error. 
19Table 7. The effect of selective drug testing on the measured proportion of recent hard drug users and of hard drug-using repeat offenders 
(n = 2858) 
Hard drug users
(Sample frequency =  38.5%)
Hard drug-using repeat offenders
(Sample frequency = 17.4%)
Testing strategy
Proportion of 
cases where a 
drug test is 
needed
Discrepancy
relative to full
testing
Number
of false 
negatives
Number of false
positives
Discrepancy
relative to full
testing
Number of 
false negatives 
Number of false
positives
No testing  0% -20.5% 263 38 -4.4% 40 18
Test all who self-report no use in 
last 3 days 69% +3.1% 0 38 +3.6% 0 18
Test all who self-report no use in 
last 3 days but some use in last 
month
8% -12.8% 178 38 0.0% 18 18
Test all who self-report no use in 
last 3 days but some use in last 
year
18% -7.6% 120 38 +2.0% 8 18
Test all who self-report no use in 
last 3 days but some use ever  27% -4.7% 88 38 +2.6% 5 18
204.2. A model-based testing strategy
The previous analysis does not make use of any information we have about the individual 
arrestees, apart from their self-reported drug use. An alternative strategy is to use our predictions 
of the probability of a false negative self-report as a basis for testing. For each individual who 
claims no drug use within the last 3 days, we use the predicted logit probability (see Table 5) of a 
positive test result conditional on personal characteristics and self-reported drug history as an 
indicator of the need to carry out a screening test. To implement this, we need to choose a cut-off 
level for the predicted probability, below which no test will be done. Thus the composite
indicator of drug use for individual i is now: 
) positive is result  test  and
otherwise 0
ˆ and days 3 last for report - self no if 1
days 3 last in use reported - self if 1
°
¯
°
®
­
!   C P D i i (3)
where  is the predicted probability of a positive drug test and C is the selected cut-off.  i P ˆ
A higher cut-off will mean fewer tests, lower survey costs but a greater risk of under-
estimation of prevalence. Table 8 summarises the effect of using this selective strategy for
alternative choices of the cut-off C. The figures quoted are (i) the proportion of cases where a test 
is required; (ii) the proportionate discrepancy between the estimate of prevalence produced by 
this approach and the result for a universal testing strategy; (iii) the sample number of false
negatives (Di = 0 and positive test result); and (iv) the sample number of false positives (Di = 1 
and negative test result). This is carried out as a measure of drug prevalence alone (with Di
defined by (3)) and as a measure of drug-using crime, with Ri defined by (2). 
21Table 8. The effect of selective drug testing on the measured proportion of recent 
hard drug users and of hard drug-using repeat offenders (n = 2858)
Hard drug users 
(Sample frequency =  38.5%)
Hard drug-using repeat 
offenders
(Sample frequency = 17.4%)
Cut-off for 
predicted
probability
Proportion
of cases 
where a 
drug test is 
needed
Discrep-
ancy
relative
to full 
testing
Number of 
false
negatives
Number of 
false
positives
Discrep-
ancy
relative
to full 
testing
Number of 
false
negatives
Number of 
false
positives
0.1 27% -5.0% 87 38 +2.4% 6 18
0.2 14% -9.4% 141 38 +0.4% 16 18
0.3 7% -13.3% 184 38 -0.6% 21 18
0.4 3% -17% 225 38 -3.0% 33 18
1.0
(no testing)  0% -20.5% 263 38 -4.4% 40 18
The choice of cut-off is clearly important. Without drug testing, prevalence of drug use is 
under-estimated by 20.5% and the prevalence of drug use and repeat offending by 4.4%. 
Predicted misreporting probabilities are generally low, so it requires a tight cut-off of C = 0.1 
before the degree of under-estimation falls below 5%. Even so, this reduces the required number
of bio-assay tests by nearly three-quarters, relative to universal testing, giving very large potential 
cost savings. For the prevalence of drugs and repeat offending, a cut-off of 0.3 (implying the need 
to test only 7% of respondents) would suffice to eliminate under-estimation almost completely.
It should be emphasised that this sort of selective testing rests heavily on the reliability 
and robustness of the statistical model of misreporting. This is not something that can be taken for 
granted, so if selective testing is to be used within a survey like NEW-ADAM, then there should 
always be a randomly-selected subset of survey subjects who are subject to universal testing and 
who can serve as a check on the validity of the selectively-administered tests. 
5. Conclusions
In this paper we have used drug-testing information collected through the New England and 
Wales Arrestee Drug Abuse Monitoring (NEW-ADAM) programme to investigate the 
validity of self-reported drug use. A review of the technical issues for drug testing suggested 
that urine and saliva were the most appropriate biological samples to use in the context of 
surveys of drug use. We examined the rates of dissonance between self-reported drug use 
within the previous 3 days and the NEW-ADAM urine test results. Although we acknowledge 
22that the NEW-ADAM data are potentially problematic due to their unrepresentative nature, 
there were substantial differences for the major drug types, with false negatives (claims of no 
recent drug use coinciding with a positive test result) predominating. Misreporting was much
more serious for cocaine and opiates than for cannabis and respondents appeared more ready 
to report accurately drug use in the distant than the recent past. This result lends support for 
the use of a relatively long recall period (e.g. 12 months) when using self-report drug 
information to monitor trends in drug prevalence. An analysis of the sensitivity of false
reporting rates to the calibration of drugs screening tests suggested that that most false
reporting is not due to test results being very close to the cut-off levels used in the tests. For 
example, only a tiny proportion of positive tests were within 10% of the NEW-ADAM cut-off 
levels, whilst the majority were at least 150% above the cut-off.
We examined the extent to which apparently false reporting of illicit drug use can be 
predicted, given information about the individual’s personal characteristics and history of 
previous drug use. We found that the risk of a false negative self-report is relatively high 
when an individual admits to some use in the past (despite claiming no use in the last three 
days). We considered a number of selective drug-testing strategies in which drug tests are 
administered to those identified as being at risk of supplying false negative self-reports, using 
personal characteristics and self-reported information on past drug use as predictors. On this 
evidence, such schemes appear capable of achieving acceptable accuracy in the measurement
of drug use whilst reducing survey costs by eliminating a large proportion of the drug tests 
that would otherwise be required. 
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